Cintia Piccina Sells 6,713 Shares of Autolus Therapeutics (NASDAQ:AUTL) Stock

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) insider Cintia Piccina sold 6,713 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $2.34, for a total value of $15,708.42. Following the completion of the transaction, the insider directly owned 13,287 shares in the company, valued at approximately $31,091.58. This represents a 33.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Autolus Therapeutics Trading Down 2.2%

AUTL stock opened at $2.24 on Friday. Autolus Therapeutics PLC Sponsored ADR has a 1-year low of $1.17 and a 1-year high of $2.58. The company has a debt-to-equity ratio of 1.04, a current ratio of 4.89 and a quick ratio of 4.40. The company has a market capitalization of $596.21 million, a price-to-earnings ratio of -2.11 and a beta of 2.10. The business has a 50 day simple moving average of $1.88 and a two-hundred day simple moving average of $1.67.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. The firm had revenue of $45.69 million for the quarter, compared to analysts’ expectations of $38.56 million. Research analysts anticipate that Autolus Therapeutics PLC Sponsored ADR will post -0.75 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Several large investors have recently bought and sold shares of AUTL. Alphabet Inc. bought a new position in Autolus Therapeutics during the second quarter valued at $1,117,000. Syncona Portfolio Ltd bought a new stake in shares of Autolus Therapeutics in the 2nd quarter worth about $26,625,152. Hennion & Walsh Asset Management Inc. raised its position in shares of Autolus Therapeutics by 2.5% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock valued at $722,000 after buying an additional 11,197 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Autolus Therapeutics by 115.6% during the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock valued at $25,000 after buying an additional 8,309 shares in the last quarter. Finally, Waverly Advisors LLC bought a new position in shares of Autolus Therapeutics in the 1st quarter valued at about $37,000. Institutional investors own 72.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on AUTL. Wall Street Zen upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday, August 3rd. Finally, Weiss Ratings raised Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Autolus Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.